Emerging therapeutic and supportive care approaches for the myelodisplastic syndromes.
Mufti
Ghulam J
GJ
D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004921:Erythropoietin / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000188:drug therapy / Q000628:therapy*; D011994:Recombinant Proteins; D033581:Stem Cell Transplantation; D019772:Topotecan / Q000627:therapeutic use
D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D007155:Immunologic Factors; D011994:Recombinant Proteins; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D019772:Topotecan; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D015254:DNA Modification Methylases